Document is current
Any future updates will be listed below
-
Authors
Gjølberg, Torleif Tollefsrud https://orcid.org/0000-0002-1719-7677
Mester, Simone https://orcid.org/0000-0002-5751-063X
Calamera, Gaia https://orcid.org/0000-0003-0689-8387
Telstad, Jenny Skjermo
Sandlie, Inger https://orcid.org/0009-0005-8063-0145
Andersen, Jan Terje https://orcid.org/0000-0003-1710-1628
-
Funding
Funding for this research was provided by:
Norges Forskningsråd (333902, 332727)
Novo Nordisk Foundation (0090894)
University of Oslo
- License Information
-
More Information
Article History
Accepted: 31 January 2025
First Online: 29 March 2025
Declarations
:
: Open access funding provided by University of Oslo (incl Oslo University Hospital). This work was partially supported by the Research Council of Norway through its Centers of Excellence scheme, project number 332727, and its Proof-of-Concept Research commercialization program, project number 333902, as well as by the Novo Nordisk Foundation Pioneer Innovator Grant 0090894.
: Torleif Tollefsrud Gjølberg, Simone Mester, Gaia Calamera, and Jenny Skjermo Telstad are employees of Authera AS. Torleif Tollefsrud Gjølberg, Simone Mester, Gaia Calamera, Jan Terje Andersen, and Inger Sandlie have ownership interests in Authera AS. Inger Sandlie and Jan Terje Andersen are inventors of the invention claimed in a patent family arising from WO2017158426 and WO2019057564 with the title “Engineered immunoglobulins with altered FcRn binding”.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: TTG, SM, and JTA conceived the overall concept, contributed to the writing of the manuscript, conducted the literature search, and supervised the manuscript development. TTG performed the majority of the writing and data extraction. SM performed the majority of the work on graphical presentations and illustrations. GC and JST contributed to the writing of the manuscript. IS provided expert opinion and contributed to the writing of the manuscript.
